AEGLEA BIOTHERAPEUTICS INC (AGLE) Stock Price, Forecast & Analysis
USA - NASDAQ:AGLE - US00773J2024 - Common Stock
AGLE Key Statistics, Chart & Performance
The current stock price of AGLE is 12.01 USD. In the past month the price increased by 12.66%. In the past year, price decreased by -3.94%.
AGLE Latest News, Press Relases and Analysis
AGLE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 22.52 | 375.96B | ||
| AMGN | AMGEN INC | 13.56 | 159.16B | ||
| GILD | GILEAD SCIENCES INC | 14.81 | 150.51B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.05 | 108.79B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.22 | 67.84B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 844.28 | 56.44B | ||
| ARGX | ARGENX SE - ADR | 61.48 | 50.76B | ||
| INSM | INSMED INC | N/A | 39.36B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.03 | 34.26B | ||
| NTRA | NATERA INC | N/A | 27.08B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.98B | ||
| BIIB | BIOGEN INC | 9.08 | 22.28B |
Related stock screener links
About AGLE
Company Profile
Aeglea Bio Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Waltham, Massachusetts and currently employs 18 full-time employees. The company went IPO on 2016-04-07. Aeglea BioTherapeutics, Inc. is a clinical-stage biotechnology company. The company is focused on human enzyme therapeutics to treat people with rare metabolic diseases. Its product candidate is Pegtarviliase, a novel polyethylene glycol modified (PEGylated), human enzyme engineered to reduce elevated levels of total homocysteine circulating in the plasma. The company has engineered pegtarviliase by directed mutagenesis of amino acids within the wild-type human cystathionine y-lyase enzyme (CGL). The Company’s second product candidate Pegzilarginase is a PEGylated, recombinant human arginase 1 that enzymatically degrades the amino acid arginine to lower arginine levels in patients with Arginase 1 Deficiency. The company has engineered pegzilarginase with modifications that enhance arginine-degrading activity of the enzyme in human plasma. The firm is engaged in advancing inflammatory bowel disease (IBD) portfolio which consists of SPY001 and SPY002, antibody candidates.
Company Info
AEGLEA BIOTHERAPEUTICS INC
221 Crescent Street, Building 23, Suite 105
Waltham MASSACHUSETTS 78746 US
CEO: Anthony G. Quinn
Employees: 18
Phone: 16176515940.0
AEGLEA BIOTHERAPEUTICS INC / AGLE FAQ
Can you describe the business of AEGLEA BIOTHERAPEUTICS INC?
Aeglea Bio Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Waltham, Massachusetts and currently employs 18 full-time employees. The company went IPO on 2016-04-07. Aeglea BioTherapeutics, Inc. is a clinical-stage biotechnology company. The company is focused on human enzyme therapeutics to treat people with rare metabolic diseases. Its product candidate is Pegtarviliase, a novel polyethylene glycol modified (PEGylated), human enzyme engineered to reduce elevated levels of total homocysteine circulating in the plasma. The company has engineered pegtarviliase by directed mutagenesis of amino acids within the wild-type human cystathionine y-lyase enzyme (CGL). The Company’s second product candidate Pegzilarginase is a PEGylated, recombinant human arginase 1 that enzymatically degrades the amino acid arginine to lower arginine levels in patients with Arginase 1 Deficiency. The company has engineered pegzilarginase with modifications that enhance arginine-degrading activity of the enzyme in human plasma. The firm is engaged in advancing inflammatory bowel disease (IBD) portfolio which consists of SPY001 and SPY002, antibody candidates.
What is the stock price of AEGLEA BIOTHERAPEUTICS INC today?
The current stock price of AGLE is 12.01 USD. The price increased by 8.79% in the last trading session.
Does AGLE stock pay dividends?
AGLE does not pay a dividend.
What is the ChartMill technical and fundamental rating of AGLE stock?
AGLE has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Should I buy AGLE stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on AGLE.
Can you provide the growth outlook for AEGLEA BIOTHERAPEUTICS INC?
The Revenue of AEGLEA BIOTHERAPEUTICS INC (AGLE) is expected to decline by -43.28% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Who owns AEGLEA BIOTHERAPEUTICS INC?
You can find the ownership structure of AEGLEA BIOTHERAPEUTICS INC (AGLE) on the Ownership tab.
AGLE Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to AGLE. When comparing the yearly performance of all stocks, AGLE is a bad performer in the overall market: 74.14% of all stocks are doing better.
AGLE Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to AGLE. AGLE scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
AGLE Financial Highlights
Over the last trailing twelve months AGLE reported a non-GAAP Earnings per Share(EPS) of -60.34. The EPS decreased by -111.72% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -142.03% | ||
| ROE | -207.78% | ||
| Debt/Equity | 0 |
AGLE Forecast & Estimates
9 analysts have analysed AGLE and the average price target is 17.85 USD. This implies a price increase of 48.63% is expected in the next year compared to the current price of 12.01.
For the next year, analysts expect an EPS growth of 78.51% and a revenue growth -43.28% for AGLE